Navigation Links
WorldHeart Appoints Morgan Brown as New Vice President of Finance and Chief Financial Officer
Date:8/10/2009

SALT LAKE CITY, Aug. 10 /PRNewswire-FirstCall/ -- ("WorldHeart", Nasdaq: WHRT) World Heart Corporation, a pioneer in cardiac assist technologies, announced today that it has appointed Morgan Brown as Executive Vice President and Chief Financial Officer. Mr. Brown brings over 16 years of experience to WorldHeart.

Mr. Brown joins WorldHeart from Lifetree Clinical Research where he was Chief Financial Officer and Senior Vice President since 2008. While at Lifetree Clinical Research, Mr. Brown oversaw the accounting, finance, human resource, facility and information technology departments.

Previously, Mr. Brown was with NPS Pharmaceuticals Inc., a Russell 2000 public company, from 2000 to 2008, where he served as Vice President Finance and Treasurer. During his tenure at NPS Mr. Brown was involved in numerous financings as well as merger and acquisition activities.

Before NPS, Mr. Brown, 40, worked for KPMG LLP in Salt Lake City. Mr. Brown managed multiple audit engagements, servicing private and publicly owned clients. Mr. Brown is a licensed certified public accountant in Utah and earned a master's degree in business administration from the University of Utah and a bachelor's degree in accounting from Utah State University.

Alex Martin, WorldHeart's President and CEO commented, "I join WorldHeart's Board of Directors and employees in welcoming Morgan to WorldHeart. Morgan brings a wealth of experience in finance and accounting that will be invaluable as WorldHeart transitions its corporate headquarters to Salt Lake City, advances its clinical development programs and grows its overall business."

In addition to his other duties, Mr. Brown will manage the move of the World Heart Headquarters from Oakland, California to Salt Lake City, Utah.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems headquartered in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the advancement of WorldHeart's clinical development programs and the growth of its overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development and market acceptance of and demand for WorldHeart's products; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009 and June 30, 2009.

www.worldheart.com


'/>"/>
SOURCE World Heart Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. WorldHeart Notified of TSX Delisting Review
3. WorldHeart Announces Possible Delisting Action by NASDAQ
4. WorldHeart Announces Voluntary Delisting from the Toronto Stock Exchange
5. WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market
6. WorldHeart Receives Favorable Decision to Continue NASDAQ Listing
7. WorldHeart Announces Effectiveness of Reverse Stock Split
8. WorldHeart Receives Notice From the NASDAQ Stock Market Regarding Non-Compliance With Marketplace Rule 4310(c)(7)
9. WorldHeart Regains Compliance With the Minimum Bid Price Rule
10. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
11. WorldHeart Appoints New President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access network. ... experts in dangerous situations the Inflow IQ team can help people. Get ready ... & refreshing knowledge systems that enhance life. , Authentically enjoy 500 ...
(Date:3/23/2017)... ... March 23, 2017 , ... On 2 March ... the US Special Operations Command’s Patriot Award. The award was presented by the ... Force Dagger Foundation for its significant and enduring support to the command. ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life testimony ... the creation of published author Bonetta Rose, a wife, mother and grandmother committed to ... by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events in the life ...
(Date:3/23/2017)... ... ... Trainer”: an electrifying and suspenseful gunslinger novel with a twist. “The Trainer” is ... an enthusiasm for action and adventure stories. , Published by Christian Faith ... at the thirty-three notches that lined the edges of the wooden grip plates of ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD announces that AB Laboratories ... in its licensed production facility under the Access to ... Hamilton, Ontario . The ... in October 2016, is currently operating at half capacity, ...
(Date:3/23/2017)... 23, 2017 Piramal Pharma ... anuncia el nombramiento de Stuart E. Needleman ... de servicios integrados completa para su base de ... clave en el crecimiento y ejecución de las ... de impulsar todas las actividades de desarrollo empresarial ...
(Date:3/23/2017)... TEL AVIV, Israel, March 23, 2017  Galmed ... or the "Company"), a clinical-stage biopharmaceutical company focused ... for the treatment of nonalcoholic steatohepatitis, or NASH, ... for the three and twelve months ended December 31, ... recently completed pre-clinical studies demonstrating Aramchol™,s potential direct ...
Breaking Medicine Technology: